Accurate Wealth Management LLC Acquires Shares of 2,483 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Accurate Wealth Management LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the first quarter, according to its most recent filing with the SEC. The fund purchased 2,483 shares of the biopharmaceutical company's stock, valued at approximately $670,000.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Alnylam Pharmaceuticals by 14.3% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock valued at $166,000 after purchasing an additional 77 shares during the last quarter. Pallas Capital Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals by 94.7% in the 1st quarter. Pallas Capital Advisors LLC now owns 6,635 shares of the biopharmaceutical company's stock worth $1,792,000 after buying an additional 3,227 shares in the last quarter. Wedmont Private Capital boosted its stake in shares of Alnylam Pharmaceuticals by 7.2% in the 1st quarter. Wedmont Private Capital now owns 1,592 shares of the biopharmaceutical company's stock valued at $430,000 after purchasing an additional 107 shares in the last quarter. TB Alternative Assets Ltd. bought a new stake in Alnylam Pharmaceuticals during the first quarter worth about $2,476,000. Finally, Whipplewood Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ALNY. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 price target for the company. Needham & Company LLC reissued a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Finally, Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $319.58.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the transaction, the chief executive officer now owns 48,948 shares of the company's stock, valued at $14,899,281.72. This represents a 39.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Up 2.3%

Shares of ALNY traded up $6.83 on Thursday, hitting $305.41. 207,056 shares of the stock traded hands, compared to its average volume of 927,442. Alnylam Pharmaceuticals, Inc. has a one year low of $152.30 and a one year high of $310.22. The business has a 50 day simple moving average of $266.98 and a 200 day simple moving average of $258.27. The company has a market capitalization of $39.82 billion, a PE ratio of -140.74 and a beta of 0.22. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the company posted ($0.16) earnings per share. The business's revenue for the quarter was up 20.2% compared to the same quarter last year. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.